Search

Your search keyword '"Rangnekar, Amol S."' showing total 140 results
Start Over Author "Rangnekar, Amol S."
140 results on '"Rangnekar, Amol S."'

1. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma

Author

Parikh, Neehar D., Jones, Patricia, Salgia, Reena, Bhan, Irun, Grinspan, Lauren T., Jou, Janice H., Zhou, Kali, Jalal, Prasun, Roccaro, Giorgio, Rangnekar, Amol S., Benhammou, Jihane N., Pillai, Anjana, Mehta, Neil, Wedd, Joel, Yang, Ju Dong, Kim, Amy K., Duarte-Rojo, Andres, Oloruntoba, Omobonike O., Tevar, Amit, Au, Jennifer S., Blain, Yamile, Rao, Sanjana, Catalano, Onofrio A., Lewis, Sara, Mendiratta-Lala, Mishal, King, Kevin, Sachdev, Lekha, Lee, Edward W., Bruno, Jill, Kamel, Ihab, Tolosa, Celestina, Kao, Karissa, Badawi, Tarek, Przybyszewski, Eric M., Quirk, Lisa, Nathani, Piyush, Haydel, Brandy, Leven, Emily, Wong, Nicole, Albertian, Robert, Chen, Ariana, Aloor, Fuad Z., Mohamed, Islam B., Elkheshen, Ahmed, Marvil, Charles, Issac, Gerard, Clinton, Joseph W., Woo, Stephanie M., Yum, Jung, Rieger, Erin, Hutchison, Alan L., Turner, Don A., Alsudaney, Manaf, Hernandez, Perla, Xu, Ziyi, Khalid, Abdullah, Barrick, Bethany, Wang, Bo, Tapper, Elliot B., Hao, Wei, and Singal, Amit G.

Published
2025
Full Text
View/download PDF

2. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea D, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Ioannou, George N, Huang, Annsa, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Kagan, Sofia, Gopal, Purva, Wong, Robert, Parikh, Neehar D, and Murphy, Caitlin C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Cancer, Emerging Infectious Diseases, Clinical Research, Hepatitis, Rare Diseases, Prevention, Infectious Diseases, Liver Cancer, Hepatitis - C, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Aged, Antiviral Agents, Carcinoma, Hepatocellular, Female, Hepatitis C, Humans, Liver Neoplasms, Male, Middle Aged, North America, Protective Factors, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, HCC, Survival, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy regarding the benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multicenter cohort study to compare overall survival between patients with HCV infection treated with DAAs and patients who did not receive DAA treatment for their HCV infection after complete response to prior HCC therapy.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC who achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 health care systems throughout the United States and Canada. We used Cox proportional hazards regression to determine the association between receipt of DAA therapy, modeled as a time-varying covariate, and all-cause mortality, accounting for informative censoring and confounding using inverse probability weighting.ResultsOf 797 patients with HCV-related HCC, 383 (48.1%) received DAA therapy and 414 (51.9%) did not receive treatment for their HCV infection after complete response to prior HCC therapy. Among DAA-treated patients, 43 deaths occurred during 941 person-years of follow-up, compared with 103 deaths during 526.6 person-years of follow-up among patients who did not receive DAA therapy (crude rate ratio, 0.23; 95% confidence interval [CI], 0.16-0.33). In inverse probability-weighted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio, 0.54; 95% CI, 0.33-0.90). This association differed by sustained virologic response to DAA therapy; risk of death was reduced in patients with sustained virologic response to DAA therapy (hazard ratio, 0.29; 95% CI, 0.18-0.47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI, 0.55-2.33).ConclusionsIn an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was associated with a significant reduction in risk of death.

Published
2019

3. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Wong, Robert, Huang, Annsa, Misra, Suresh, Schwartz, Myron, Mitrani, Robert, Nakka, Sasank, Noureddine, Wassim, Ho, Chanda, Konjeti, Venkata R, Dao, Alexander, Nelson, Kevin, Delarosa, Kelly, Rahim, Usman, Mavuram, Meher, Xie, Jesse J, Murphy, Caitlin C, and Parikh, Neehar D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Emerging Infectious Diseases, Digestive Diseases, Rare Diseases, Hepatitis - C, Hepatitis, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Cancer, Cancer, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antiviral Agents, Canada, Carcinoma, Hepatocellular, Female, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Sustained Virologic Response, Time Factors, United States, Hepatitis C Virus, Recurrence, Direct-Acting Antiviral, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response).ResultsOf 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance.ConclusionIn a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

Published
2019

5. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma

Author

Rich, Nicole E., Yang, Ju Dong, Perumalswami, Ponni V., Alkhouri, Naim, Jackson, Whitney, Parikh, Neehar D., Mehta, Neil, Salgia, Reena, Duarte-Rojo, Andres, Kulik, Laura, Rakoski, Mina, Said, Adnan, Oloruntoba, Omobonike, Ioannou, George N., Hoteit, Maarouf A., Moon, Andrew M., Rangnekar, Amol S., Eswaran, Sheila L., Zheng, Elizabeth, Jou, Janice H., Hanje, James, Pillai, Anjana, Hernaez, Ruben, Wong, Robert, Scaglione, Steven, Samant, Hrishikesh, Kapuria, Devika, Chandna, Shaun, Rosenblatt, Russell, Ajmera, Veeral, Frenette, Catherine T., Satapathy, Sanjaya K., Mantry, Parvez, Jalal, Prasun, John, Binu V., Fix, Oren K., Leise, Michael, Lindenmeyer, Christina C., Flores, Avegail, Patel, Nayan, Jiang, Z. Gordon, Latt, Nyan, Dhanasekaran, Renumathy, Odewole, Mobolaji, Kagan, Sofia, Marrero, Jorge A., and Singal, Amit G.

Published
2020
Full Text
View/download PDF

10. COVID-19-Associated Liver Injury

Author

Gildea,Daniel T, Woo,Stephanie M, O'Connor,Corinne E, Rangnekar,Amol S, Gildea,Daniel T, Woo,Stephanie M, O'Connor,Corinne E, and Rangnekar,Amol S

Abstract

Daniel T Gildea,1 Stephanie M Woo,2 Corinne E O’Connor,3 Amol S Rangnekar4 1Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC, USA; 2Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA; 3Georgetown University School of Medicine, Washington, DC, USA; 4MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USACorrespondence: Daniel T Gildea, Tel +1 302-985-7777, Email daniel.gildea@medstar.netAbstract: This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.Keywords: COVID-19, cholangiopathy, DILI, hepatitis, transplant, liver

Published
2023

20. Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States

Author

Samala, Niharika, primary, Wang, Richard Y., additional, Auh, Sungyoung, additional, Balla, Abdalla Kara, additional, Dakhoul, Lara, additional, Alter, Harvey J., additional, Farci, Patrizia, additional, Ghabril, Marwan, additional, Lucey, Michael R., additional, Rangnekar, Amol S., additional, Reddy, K. Rajender, additional, and Ghany, Marc G., additional

Published
2022
Full Text
View/download PDF

21. Alcohol‐associated liver disease predicts increased post‐liver transplant opioid use

Author

Johnson‐Laghi, Krystina A., primary, Woo, Stephanie M., additional, Zafar, Zaeema, additional, Fernandez, Stephen, additional, Desale, Sameer, additional, Robertazzi, Suzanne E., additional, Smith, Coleman I., additional, Thomas, Arul M., additional, Lalos, Alexander T., additional, Georgia, Sarah J., additional, Jenkins, Michelle L., additional, Faust, Thomas W., additional, Fishbein, Thomas M., additional, Satoskar, Rohit S., additional, Rangnekar, Amol S., additional, and Hsu, Christine C., additional

Published
2022
Full Text
View/download PDF

24. Infections in Liver Transplantation

Author

Mohanraj, B. Sharmila, Rangnekar, Amol S., and Timpone, Joseph G.

Subjects
Healthcare-acquired infections, surgical procedures, operative, Deceased donor transplant, Antirejection drugs, Orthotopic liver transplant, Opportunistic infections, Recurrence of viral hepatitis post-transplant, End-stage liver disease, Infectious complications of liver transplant, Article, Acute liver failure, Chronic hepatitis C infection, Living donor transplant
Abstract

Liver transplantation has become an important treatment modality for patients with end-stage liver disease/cirrhosis, acute liver failure, and hepatocellular carcinoma. Although surgical techniques and immunosuppressive regimens for liver transplantation have improved significantly over the past 20 years, infectious complications continue to contribute to the morbidity and mortality in this patient population. The use of standardized screening protocols for both donors and recipients, coupled with targeted prophylaxis against specific pathogens, has helped to mitigate the risk of infection in liver transplant recipients. Patients with chronic liver disease and cirrhosis have immunological deficits that place them at increased risk for infection while awaiting liver transplantation. The patient undergoing liver transplantation is prone to develop healthcare-acquired infections due to multidrug-resistant organisms that could potentially affect patient outcomes after transplantation. The complex nature of liver transplant surgery that involves multiple vascular and hepatobiliary anastomoses further increases the risk of infection after liver transplantation. During the early post-transplantation period, healthcare-acquired bacterial and fungal infections are the most common types of infection encountered in liver transplant recipients. The period of maximal immunosuppression that occurs at 1–6 months after transplantation can be complicated by opportunistic infections due to both primary infection and reactivation of latent infection. Severe community-acquired infections can complicate the course of liver transplantation beyond 12 months after transplant surgery. This chapter provides an overview of liver transplantation including indications, donor-recipient selection criteria, surgical procedures, and immunosuppressive therapies. A focus on infections in patients with chronic liver disease/cirrhosis and an overview of the specific infectious complications in liver transplant recipients are presented.

Published
2018

34. SAT-471-Hepatic adenomatosis increases risk of hepatic adenoma bleeding

Author

Mcdermott, Chelsea, primary, Hsu, Christine Cho-Shing, additional, Desale, Sameer, additional, Fernandez, Stephen, additional, Ertreo, Marco, additional, Jha, Reena C., additional, Satoskar, Rohit S., additional, Lalos, Alexander T., additional, Rangnekar, Amol S., additional, Thomas, Arul M., additional, Smith, Coleman I., additional, and Faust, Thomas W., additional

Published
2019
Full Text
View/download PDF

36. Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection

Author

Di Poto, Cristina, primary, He, Shisi, additional, Varghese, Rency S., additional, Zhao, Yi, additional, Ferrarini, Alessia, additional, Su, Shan, additional, Karabala, Abdullah, additional, Redi, Mesfin, additional, Mamo, Hassen, additional, Rangnekar, Amol S., additional, Fishbein, Thomas M., additional, Kroemer, Alexander H., additional, Tadesse, Mahlet G., additional, Roy, Rabindra, additional, Sherif, Zaki A., additional, Kumar, Deepak, additional, and Ressom, Habtom W., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results